Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly’s best-selling diabetes drug Mounjaro lowered the risk of heart attacks and stroke in a late-stage trial, the ...

Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some ...

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Novo Nordisk is a healthcare stock that is down 50% in 2025. Is NVO stock undervalued at current levels or can it move lower over the next 12 months?

Just six weeks ago, things seemed to be getting better for Novo Nordisk A/S. Investors were optimistic, and the Danish drugmaker was briefly Europe’s most valuable public company again. Now, the stock ...

President Donald Trump's new European tariffs could significantly increase the cost of Novo Nordisk's weight loss drug, Ozempic.

Analysts say this approval could significantly expand Alhemo's market potential. The hemophilia space is becoming ...

The fall comes after U.S. President Donald Trump on Thursday sent letters to 17 major pharmaceutical firms, including Novo ...